Accessibility Menu

GeneLink

(OTC) GNLKQ

Current Price$0.00
Market Cap$10.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)-100%
5 Year-90%
1 Year+300%
1 Month+0%

GeneLink Financials at a Glance

Market Cap

$10.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.73M

Net Income (TTM)

-$2.23M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

34.74 (High)

Price

$0.00

Volume

510,656

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

GNLKQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GeneLink

Industry

Biotechnology

Headquarters

Orlando, FL 32809, US

GNLKQ Financials

Key Financial Metrics (TTM)

Gross Margin

21.75%

Operating Margin

-162.40%

Net Income Margin

-142.86%

Return on Equity

147.34%

Return on Capital

N/A

Return on Assets

-209.77%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

265.02M

Volume

510.66K

Avg. Volume

0

Financials (TTM)

Gross Profit

$456.40K

Operating Income

-$2.22M

EBITDA

-$1.19M

Operating Cash Flow

-$1.13M

Capital Expenditure

-$4.51K

Free Cash Flow

-$1.14M

Cash & ST Invst.

$127.56K

Total Debt

$1.19M

GeneLink Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2013YOY CHG

Revenue

$294.74K

-30.7%

Gross Profit

$72.51K

+180.8%

Gross Margin

24.60%

N/A

Market Cap

$10.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$757.14

N/A

Employees

14

N/A

Net Income

-$539.29K

+44.7%

EBITDA

-$584.34K

+32.8%

Quarterly Fundamentals

Name
Q3 2013YOY CHG

Total Cash

$127.56K

-86.9%

Total Debt

$1.19M

+12.6%

Accounts Receivable

$146.35K

-1.2%

Inventory

$337.58K

-20.9%

Long Term Debt

$1.19M

+12.6%

Short Term Debt

$0.00

N/A

Return on Assets

-2.10%

N/A

Return on Invested Capital

9.03%

N/A

Free Cash Flow

-$65.88K

+89.9%

Operating Cash Flow

-$65.88K

+89.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNBXCNBX Pharmaceuticals Inc.
$0.00+50.00%
RGINRegenicin, Inc.
$0.00+0.00%
ITMCItoco Inc.
$0.00+0.00%
GMVDFG Medical Innovations Holdings Ltd
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$72.64-0.06%
CLSKCleanSpark
$12.36-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$39.95+0.06%
PLTRPalantir Technologies
$130.04+0.03%

Questions About GNLKQ

What is the current price of GeneLink?

GeneLink is trading at $0.00 per share.

What is the 52-week range for GeneLink?

Over the past 52 weeks, GeneLink has traded between $0.00 and $0.00.

How much debt does GeneLink have?

GeneLink total debt is unavailable.

How much cash does GeneLink have on hand?

GeneLink does not have cash on hand data available.

What is GeneLink’s dividend yield?

GeneLink does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.